{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:37:11Z","timestamp":1790807831987,"version":"4.1.0"},"reference-count":32,"publisher":"American Chemical Society (ACS)","issue":"8","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/501100017683","name":"Dalian Science and Technology Innovation Fund","doi-asserted-by":"publisher","award":["2024JJ12PT013"],"award-info":[{"award-number":["2024JJ12PT013"]}],"id":[{"id":"10.13039\/501100017683","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Basic Research Project of Liaoning Provincial Department of Education for Universities"},{"name":"State Key Laboratory of Neurology and Oncology Drug Development","award":["SIML-202404"],"award-info":[{"award-number":["SIML-202404"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor with an inferior prognosis, and currently, there is a lack of effective treatment options. In immunotherapy, messenger RNA (mRNA)-based drugs, especially mRNA vaccines, have shown great potential in recent years. Previous research has found that high-temperature requirement protein A1 (HTRA1) is upregulated in PDAC and is a key factor in disease progression. Based on this key discovery, we have developed an mRNA drug based on lipid nanoparticles (LNP), which utilizes the efficient delivery capability of LNP to achieve precise delivery of antibodies targeting HTRA1 in vivo, thereby directly inhibiting the expression of HTRA1 in tumor cells. As a delivery carrier, LNP not only improves the stability and bioavailability of mRNA but also enhances its enrichment and release efficiency in tumor tissues. This study confirms that anti-HTRA1 (\u03b1HTRA1) mRNA can effectively inhibit the malignant phenotype of PDAC cells. Furthermore, we have established C57BL\/6 wild-type (WT) and LSL-KrasG12D\/+; Pdx1-Cre (KC) mouse pancreatic organoid models, and the results indicate that the drug, by inhibiting the hypoxia-inducible factor-1 (HIF-1) signaling pathway, improves the tumor microenvironment and can effectively suppress the progression of PDAC. The mRNA drugs based on LNP designed and synthesized in this study have good therapeutic potential for PDAC, providing new potential drugs for targeted therapy of PDAC.<\/jats:p>","DOI":"10.1021\/acs.bioconjchem.6c00013","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T03:33:31Z","timestamp":1778643211000},"page":"1551-1561","source":"Crossref","is-referenced-by-count":1,"title":["Lipid Nanoparticle-Based\n\u03b1HTRA1 mRNA Improves\nPancreatic Ductal Adenocarcinoma Redox Microenvironment by Suppressing\nHTRA1\/HIF-1 Signaling"],"prefix":"10.1021","volume":"37","author":[{"given":"Xinya","family":"Zhao","sequence":"first","affiliation":[{"name":"First Affiliated Hospital of Dalian Medical University , , ,","place":["Dalian, China, 116011"]},{"name":"Dalian Medical University , , ,","place":["Dalian, China, 116044"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4416-2234","authenticated-orcid":true,"given":"Xufeng","family":"Tao","sequence":"additional","affiliation":[{"name":"First Affiliated Hospital of Dalian Medical University , , ,","place":["Dalian, China, 116011"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Xiang","sequence":"additional","affiliation":[{"name":"First Affiliated Hospital of Dalian Medical University , , ,","place":["Dalian, China, 116011"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Kong","sequence":"additional","affiliation":[{"name":"First Affiliated Hospital of Dalian Medical University , , ,","place":["Dalian, China, 116011"]},{"name":"Dalian Medical University , , ,","place":["Dalian, China, 116044"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaonan","family":"Zhang","sequence":"additional","affiliation":[{"name":"First Affiliated Hospital of Dalian Medical University , , ,","place":["Dalian, China, 116011"]},{"name":"Dalian Medical University , , ,","place":["Dalian, China, 116011"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wu","sequence":"additional","affiliation":[{"name":"First Affiliated Hospital of Dalian Medical University , , ,","place":["Dalian, China, 116011"]},{"name":"Dalian Medical University , , ,","place":["Dalian, China, 116011"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangyue","family":"Guo","sequence":"additional","affiliation":[{"name":"First Affiliated Hospital of Dalian Medical University , , ,","place":["Dalian, China, 116011"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deshi","family":"Dong","sequence":"additional","affiliation":[{"name":"First Affiliated Hospital of Dalian Medical University , , ,","place":["Dalian, China, 116011"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"issue":"1","key":"2026081907211470000_cit1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"2","key":"2026081907211470000_cit2","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1053\/j.gastro.2022.03.056","article-title":"Pancreatic Cancer:\nPathogenesis, Screening, Diagnosis, and Treatment","volume":"163","author":"Wood","year":"2022","journal-title":"Gastroenterology"},{"issue":"7","key":"2026081907211470000_cit3","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1053\/j.gastro.2019.01.259","article-title":"Early Detection\nof\nPancreatic Cancer: Opportunities and Challenges","volume":"156","author":"Singhi","year":"2019","journal-title":"Gastroenterology"},{"issue":"10","key":"2026081907211470000_cit4","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/s41419-024-07145-z","article-title":"The interaction\nbetween\nUBR7 and PRMT5 drives PDAC resistance to gemcitabine by regulating\nglycolysis and immune microenvironment","volume":"15","author":"Feng","year":"2024","journal-title":"Cell\nDeath Dis."},{"issue":"6","key":"2026081907211470000_cit5","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1016\/j.cell.2018.11.013","article-title":"Long-Term Expansion of Functional\nMouse and Human Hepatocytes as 3D Organoids","volume":"175","author":"Hu","year":"2018","journal-title":"Cell"},{"issue":"4","key":"2026081907211470000_cit6","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.3390\/biomedicines11041058","article-title":"Replacement, Reduction,\nand Refinement of Animal Experiments in Anticancer Drug Development:\nThe Contribution of 3D In Vitro Cancer Models in the Drug Efficacy\nAssessment","volume":"11","author":"Tosca","year":"2023","journal-title":"Biomedicines"},{"issue":"10","key":"2026081907211470000_cit7","doi-asserted-by":"publisher","first-page":"a031575","DOI":"10.1101\/cshperspect.a031575","article-title":"Kras in Organoids","volume":"8","author":"Cheng","year":"2018","journal-title":"Cold Spring\nHarb. Perspect. Med."},{"issue":"12","key":"2026081907211470000_cit8","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.3390\/pharmaceutics14122709","article-title":"Advances in\nTumor Organoids for the Evaluation of Drugs: A Bibliographic Review","volume":"14","author":"London\u0303o-Berrio","year":"2022","journal-title":"Pharmaceutics"},{"key":"2026081907211470000_cit9","doi-asserted-by":"publisher","first-page":"1061388","DOI":"10.3389\/fimmu.2022.1061388","article-title":"Cancer organoid\nco-culture model system: Novel approach\nto guide precision medicine","volume":"13","author":"Yuan","year":"2023","journal-title":"Front. Immunol."},{"issue":"9","key":"2026081907211470000_cit10","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1016\/j.stem.2025.07.008","article-title":"A pancreatic\ncancer organoid biobank links multi-omics signatures to therapeutic\nresponse and clinical evaluation of statin combination therapy","volume":"32","author":"Li","year":"2025","journal-title":"Cell Stem Cell"},{"issue":"1","key":"2026081907211470000_cit11","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12943-025-02374-y","article-title":"Establishing\n3D organoid models from patient-derived conditionally reprogrammed\ncells to bridge preclinical and clinical insights in pancreatic cancer","volume":"24","author":"Kim","year":"2025","journal-title":"Mol. Cancer"},{"issue":"18","key":"2026081907211470000_cit12","doi-asserted-by":"publisher","first-page":"10166","DOI":"10.3390\/ijms251810166","article-title":"Development of mRNA Lipid Nanoparticles:\nTargeting and Therapeutic\nAspects","volume":"25","author":"Liu","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"16","key":"2026081907211470000_cit13","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1039\/D2TB02782H","article-title":"mRNA therapeutics\nfor disease therapy: principles, delivery, and clinical translation","volume":"11","author":"Zhou","year":"2023","journal-title":"J. Mater. Chem. B"},{"issue":"1","key":"2026081907211470000_cit14","doi-asserted-by":"publisher","first-page":"96","DOI":"10.7150\/thno.89247","article-title":"Path towards mRNA delivery for cancer\nimmunotherapy from bench to bedside","volume":"14","author":"Chen","year":"2024","journal-title":"Theranostics"},{"key":"2026081907211470000_cit15","doi-asserted-by":"publisher","first-page":"122628","DOI":"10.1016\/j.biomaterials.2024.122628","article-title":"mRNA vaccines\ncontribute to innate\nand adaptive immunity to enhance immune response in vivo","volume":"310","author":"Cao","year":"2024","journal-title":"Biomaterials"},{"key":"2026081907211470000_cit16","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1038\/s41587-024-02424-8","article-title":"Building better mRNA\nfor therapeutics","volume":"43","author":"Liu","year":"2024","journal-title":"Nat.\nBiotechnol."},{"issue":"1","key":"2026081907211470000_cit17","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41392-022-01007-w","article-title":"mRNA-based therapeutics:\npowerful and versatile tools\nto combat diseases","volume":"7","author":"Qin","year":"2022","journal-title":"Signal Transduct. Target.\nTher."},{"issue":"4","key":"2026081907211470000_cit18","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.ymthe.2019.02.012","article-title":"Delivering the Messenger:\nAdvances in Technologies for Therapeutic mRNA Delivery","volume":"27","author":"Kowalski","year":"2019","journal-title":"Mol. Ther."},{"key":"2026081907211470000_cit19","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jconrel.2022.05.042","article-title":"Focused ultrasound\/microbubbles-assisted\nBBB opening enhances LNP-mediated mRNA delivery to brain","volume":"348","author":"Ogawa","year":"2022","journal-title":"J. Controlled Release"},{"key":"2026081907211470000_cit20","doi-asserted-by":"publisher","first-page":"114961","DOI":"10.1016\/j.addr.2023.114961","article-title":"Advancements\nof in vitro transcribed mRNA (IVT mRNA)\nto enable translation into the clinics","volume":"199","author":"Kang","year":"2023","journal-title":"Adv.\nDrug Delivery Rev."},{"issue":"5","key":"2026081907211470000_cit21","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1016\/j.ajpath.2013.02.003","article-title":"The emerging roles\nof HTRA1 in musculoskeletal disease","volume":"182","author":"Tiaden","year":"2013","journal-title":"Am. J.\nPathol."},{"issue":"11","key":"2026081907211470000_cit22","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.3390\/diagnostics12112705","article-title":"HtrA1 in Gestational Diabetes Mellitus: A Possible\nBiomarker?","volume":"12","author":"Tossetta","year":"2022","journal-title":"Diagnostics"},{"issue":"1","key":"2026081907211470000_cit23","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41420-024-01806-w","article-title":"Carfilzomib relieves pancreatitis-initiated\npancreatic ductal adenocarcinoma\nby inhibiting high-temperature requirement protein A1","volume":"10","author":"Guo","year":"2024","journal-title":"Cell Death Discovery"},{"issue":"11","key":"2026081907211470000_cit24","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e20969","article-title":"Regulatory role of RNA modifications\nin the treatment of pancreatic ductal adenocarcinoma (PDAC)","volume":"9","author":"Chen","year":"2023","journal-title":"Heliyon"},{"issue":"31","key":"2026081907211470000_cit25","doi-asserted-by":"publisher","first-page":"4260","DOI":"10.1038\/s41388-018-0258-4","article-title":"Inactivation\nof the serine protease HTRA1 inhibits tumor growth by deregulating\nangiogenesis","volume":"37","author":"Klose","year":"2018","journal-title":"Oncogene"},{"issue":"2","key":"2026081907211470000_cit26","doi-asserted-by":"publisher","DOI":"10.1111\/cns.14605","article-title":"HTRA1 promotes\nEMT through the HDAC6\/Ac-\u03b1-tubulin pathway in\nhuman GBM cells","volume":"30","author":"Zhao","year":"2024","journal-title":"CNS Neurosci. Ther."},{"issue":"8","key":"2026081907211470000_cit27","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/sj.onc.1207271","article-title":"A candidate tumor suppressor HtrA1\nis downregulated\nin ovarian cancer","volume":"23","author":"Chien","year":"2004","journal-title":"Oncogene"},{"issue":"3","key":"2026081907211470000_cit28","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1158\/1078-0432.CCR-09-3069","article-title":"Expression\nand functional significance of HtrA1 loss in endometrial cancer","volume":"17","author":"Mullany","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"2026081907211470000_cit29","doi-asserted-by":"publisher","first-page":"1494206","DOI":"10.3389\/fimmu.2024.1494206","article-title":"Effective\ncancer immunotherapy combining mRNA-encoded bispecific antibodies\nthat induce polyclonal T cell engagement and PD-L1-dependent 4\u20131BB\ncostimulation","volume":"15","author":"Hangiu","year":"2025","journal-title":"Front. Immunol."},{"issue":"1","key":"2026081907211470000_cit30","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1038\/s41467-025-57149-2","article-title":"LNP-RNA-mediated antigen\npresentation\nleverages SARS-CoV-2-specific immunity for cancer treatment","volume":"16","author":"Xue","year":"2025","journal-title":"Nat. Commun."},{"issue":"9","key":"2026081907211470000_cit31","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1026535","article-title":"HIF-1 is a\ncritical target of pancreatic cancer","volume":"4","author":"Hao","year":"2015","journal-title":"OncoImmunology"},{"issue":"1","key":"2026081907211470000_cit32","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1038\/s41467-022-29684-9","article-title":"USP25 promotes pathological HIF-1-driven\nmetabolic reprogramming and is a potential therapeutic target in pancreatic\ncancer","volume":"13","author":"Nelson","year":"2022","journal-title":"Nat. Commun."}],"container-title":["Bioconjugate Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.bioconjchem.6c00013","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/bcches\/article-pdf\/37\/8\/1551\/63505826\/acs.bioconjchem.6c00013.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/bcches\/article-pdf\/37\/8\/1551\/63505826\/acs.bioconjchem.6c00013.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T11:54:24Z","timestamp":1787140464000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/bcches\/article\/37\/8\/1551\/5092130\/Lipid-Nanoparticle-Based-HTRA1-mRNA-Improves"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":32,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,5,12]]},"published-print":{"date-parts":[[2026,8,19]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.bioconjchem.6c00013","relation":{},"ISSN":["1043-1802","1520-4812"],"issn-type":[{"value":"1043-1802","type":"print"},{"value":"1520-4812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]}}}